Sarcomatoid Mesothelioma Treatment Focuses on Two-Drug Combo
Researchers in Spain are developing what they hope will be a more effective sarcomatoid mesothelioma treatment. The new treatment focuses on a pair of drugs that are already being tested in humans. Mesothelioma impacts about 2,500 Americans each year. Sarcomatoid mesothelioma is a rare form of this rare cancer. About a quarter of the annual cases are sarcomatoid. This form of cancer is even more aggressive than epithelioid mesothelioma. But sarcomatoid mesothelioma treatment is not significantly different. Neither are the results. But the new study could change the prognosis for people with asbestos cancer. It appears in the journal Cancer Research. Chemotherapy is the Primary Sarcomatoid Mesothelioma Treatment Most people with malignant mesothelioma receive chemotherapy with cisplatin and Alimta. This … Continue reading Sarcomatoid Mesothelioma Treatment Focuses on Two-Drug Combo
Anti-Inflammatory Treatment for Mesothelioma Shows Long-Term Benefit
Doctors in London are reporting a case of long-term mesothelioma survival with anti-inflammatory treatment for mesothelioma. The 64-year-old pleural mesothelioma patient had been a heating engineer. When he was diagnosed with pleural mesothelioma, he elected not to have standard cancer treatments. His doctors advised him to start on a regimen of aspirin and other anti-inflammatory drugs. On just the anti-inflammatory treatment for mesothelioma, the man was still alive four years after his diagnosis. Mesothelioma and Inflammation Pleural mesothelioma is an aggressive cancer of the membrane around the lungs. It is most common in people who have worked or lived around asbestos. When asbestos fibers get into the lungs, they stay there permanently. Studies suggest that the inflammation caused by these … Continue reading Anti-Inflammatory Treatment for Mesothelioma Shows Long-Term Benefit
Second-Line Treatment for Mesothelioma with Lurbinectedin
Swiss researchers may have finally found an effective second-line treatment for mesothelioma. Scientists with the Swiss Group for Clinical Cancer Research presented their findings at the recent European Society for Medical Oncology conference in Barcelona. Mesothelioma patients who fail after first-line therapy have few options. The new study focused on lurbinectedin, a drug that impacts cancer cells at the DNA level. Early studies suggest lurbinectedin might make a good second-line treatment for small cell lung cancer. According to the Swiss team, more than half of patients in their study responded to lurbinectedin as a second-line treatment for mesothelioma. In Search of a Second-Line Mesothelioma Treatment Malignant mesothelioma is notoriously difficult to diagnose and even harder to treat. It is usually … Continue reading Second-Line Treatment for Mesothelioma with Lurbinectedin
New Mesothelioma Immunotherapy Trial Now Underway at Baylor
Cancer researchers at Baylor College of Medicine have launched a new mesothelioma immunotherapy trial. The trial combines the cancer drug Opdivo (nivolumab) with injections of a modified virus called MTG201. Baylor scientists are hoping to recruit 12 pleural mesothelioma patients whose cancer has come back after chemotherapy. The treatment combination appeared to work well in mice with mesothelioma. If it works as well in people, this new mesothelioma immunotherapy trial could change the outlook for many people with malignant mesothelioma. How the New Mesothelioma Immunotherapy Trial Will Work Opdivo is the brand name for nivolumab. It blocks a protein called PD-1 in cancer cells. PD-1 is one of the ways that mesothelioma cells evade the immune system. Opdivo is often … Continue reading New Mesothelioma Immunotherapy Trial Now Underway at Baylor
Cediranib for Mesothelioma: VEGF Inhibitor Fails Another Trial
Cediranib for mesothelioma appears to be ruled out by another failed clinical trial. A new study led by MD Anderson researchers concludes that the VEGF inhibitor causes too many side effects for not enough survival benefit. It is a blow to researchers hoping to use cediranib for mesothelioma patients on chemotherapy. Cutting Off Tumor Blood Supply Cediranib is an oral drug made by AstraZeneca. It is part of a class of drugs called VEGF inhibitors. Vascular endothelial growth factor (VEGF) is a signal protein that stimulates blood vessel formation in tumors. Research shows that mesothelioma patients who have higher serum levels of VEGF have a lower chance of survival. VEGF inhibitors like cediranib latch onto VEGF receptors inside mesothelioma cells. … Continue reading Cediranib for Mesothelioma: VEGF Inhibitor Fails Another Trial
Experimental Mesothelioma Treatment Targets Tumor Growth Compounds
Hong Kong researchers have released the first results of an experimental mesothelioma treatment they are working on. The treatment targets organic compounds believed to contribute to mesothelioma growth. The trial took place at the University of Hong Kong. Mice with mesothelioma received doses of an enzyme inhibitor called DFMO. The drug appears to stop the production of organic compounds called polyamines. In tests, mice with lower polyamine levels lived longer with pleural mesothelioma. Enzymes Contribute to Tumor Growth The growth and spread of pleural mesothelioma is a complex process. It involves many different proteins and enzymes working together. Scientists have not yet identified all of the compounds that contribute to cancer growth. But the experimental mesothelioma treatment in Hong Kong … Continue reading Experimental Mesothelioma Treatment Targets Tumor Growth Compounds
Treating Advanced Peritoneal Mesothelioma with Spray-On Oxaliplatin
European doctors have tested a new spray-on cancer drug that could be another treatment option for people with advanced peritoneal mesothelioma. The drug is oxaliplatin. It is sold under the brand name Eloxatin. It is normally given by injection into a vein. But that can cause serious side effects, including stomach pain. A new study published in the European Journal of Surgical Oncology suggests there may be a more effective way to get the benefits of oxaliplatin. Researchers found that using it as a spray for advanced peritoneal mesothelioma extended survival with fewer side effects. PIPAC for Advanced Peritoneal Mesothelioma As Surviving Mesothelioma first reported last spring, pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new way to deliver cancer medicines. … Continue reading Treating Advanced Peritoneal Mesothelioma with Spray-On Oxaliplatin
Ofev Shelved as a Treatment for Pleural Mesothelioma
It is official – the VEGF inhibitor Ofev is out of the running as a treatment for pleural mesothelioma. Hopes had been high for this drug after initial results showed a survival advantage. For the last two years, Ofev (nintedanib) was the subject of a large, international clinical trial. But now the leaders of that trial have published their Phase III trial results in The Lancet: Respiratory Medicine. They show that Ofev did not extend survival and is not an effective treatment for pleural mesothelioma. Why Hopes Were High for Ofev Ofev is an oral medication that stops cancer cells from producing a protein called VEGF. VEGF promotes the growth of blood vessels that help mesothelioma tumors grow. VEGF may … Continue reading Ofev Shelved as a Treatment for Pleural Mesothelioma
Combination Mesothelioma Therapy Begins Pivotal Trial
A combination mesothelioma therapy that showed promise in early trials is finally being studied on a larger scale. The power-packed chemo-immuno-gene therapy known as TR002 has the potential to change the outlook for thousands of malignant mesothelioma patients. A small trial of the combination mesothelioma therapy in 2016 produced “significantly higher” mesothelioma survival rates than most patients are told to expect. Drug company Trizell announced last month that the combination will now be tested on 300 patients at sites in the US, Europe, Australia and Russia. Combination Mesothelioma Therapy Starts with Gene Therapy TR002 is an investigational gene therapy for mesothelioma patients who have failed first-line chemotherapy. This combination mesothelioma therapy is based on the human interferon-alpha 2b gene. The … Continue reading Combination Mesothelioma Therapy Begins Pivotal Trial
New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy
A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its … Continue reading New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!